Prof Adam Rosenthal explores the potential for more personalised care for patients at risk of ovarian cancer not yet ready to ...

Insights from the BSAC New Agents Conference focused on emergent fungal and viral disease threats and therapeutic innovations ...

New response thresholds for RA demonstrate improved correlation with ultrasound-detected synovitis and ability to refine ...

A novel risk calculator integrating comorbidities and gut-derived biomarkers stratifies risk of rehospitalisation and death ...

The impact of the TB resurgence and multidrug resistance on clinical practice will be explored at Clinical Excellence in ...

Using CDK4/6 inhibitors as first-line therapy in advanced breast cancer does not improve overall survival compared with ...

ECCO’26 focused on holistic care for inflammatory bowel disease, with multiple presentations focusing on ustekinumab ...

Two complementary genome-wide association studies provide new insights into how host genetics influence the human gut ...

Prof Colin Berry describes stress CMR-based myocardial blood flow endotyping for patients with chest pain and unobstructed ...

The JAK inhibitor deuruxolitinib has been approved by the MHRA as a treatment option for adults with severe alopecia areata.

Early prophylactic hydrocortisone for extremely preterm infants may increase BPD-free survival without raising rates of complications.

A PSA test in midlife could help to identify men at low risk of prostate cancer, supporting screening strategies and reducing overdiagnosis.